The U.S. Food and Drug Administration (FDA) approved Poherdy (pertuzumab-dpzb) as the first interchangeable biosimilar to ...

After the FDA rejected its spinocerebellar ataxia treatment, Biohaven missed out on a $150 million payment from Oberland Capital. Now the company is reshuffling its pipeline to stay alive.

According to DataM Intelligence AUSTIN, Texas and TOKYO, Nov. 18, 2025 /PRNewswire/ -- DataM Intelligence announces the latest insights into the rapidly transforming Oncology Molecular Diagnostics ...

Ongoing research in renal cell carcinoma (RCC) suggests that hypoxia-inducible factor 2-alpha (HIF-2α) inhibitors are poised ...

Applied Therapeutics’ lack of progress on govorestat as well as the potential costs to come have led analysts to question ...

Drug & Device Team provides recommendations based on Food & Drug Administration (FDA) draft guidance on Quality Management System ...

CRRT (Continuous Renal Replacement Therapy): A form of dialysis used for critically ill patients that continuously removes ...

CHICAGO — De novo autoimmune diseases, including myositis, vasculitis and lupus, may occur after chimeric antigen receptor ...

A chatbot might return a single response based on an editorial or opinion piece it "remembers," presenting it as definitive.

Anonymized data shared with pharma will remain hidden from public after two-year legal battle, based on hidden evidence of "triangulating" the deceased's identities and assumption their relatives ...

Dr. Paul Bowary’s Arzilence Psychiatry receives a 2025 Global Recognition Award for merging precision psychiatry with digital ...

Improved insurance coverage likely drove increased adoption of Semglee (insulin glargine-yfgn) rather than its status as an interchangeable biosimilar of Lantus, according to new research published in ...